EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Qualitative StudieOpen Access · CC BY-NC 4.0

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants

Carla Dias-Barbosa, Hisaka Igarashi, Ashley Duenas, Asha Hareendran, Shigekazu Kitamura, Shigeya Tanaka, Naoko Sanno, Hikaru Doi, Tsutomu Nagamitsu, Yoshihisa Tatsuoka, Yasuhiko Matsumori, Miki Hasebe und 1 weitere

The Patient - Patient-Centered Outcomes Research · 2026

DOI: 10.1007/s40271-026-00813-6 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Patient - Patient-Centered Outcomes Research, 2026. Verfasst von Carla Dias-Barbosa und 12 weiteren Autor:innen. Beteiligte Einrichtung: PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, UK. carla.dias-barbosa@evidera.com. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In Japan, migraine is estimated to affect 6-8.6% of the population, and the burden of migraine and barriers to migraine care are substantial. Although new preventive treatments are available for migraine, there is limited qualitative information about the lived experience of adults with migraine in Japan and how these treatments improve their day-to-day lives. METHODS: Participants in a qualitative interview study embedded in a phase 3 randomized, double-blind, placebo-controlled clinical trial (NCT03812224) were invited to take part in a telephone interview after completing 24 weeks of double-blind treatment with once-monthly erenumab 70 mg and a subsequent 28-week open-label treatment period. Interviews were conducted by Japanese interviewers using a semi-structured interview guide. The interviews were audio-recorded, transcribed, and qualitatively analysed using a thematic content analysis approach. RESULTS: Forty-one participants were interviewed between May and September 2020. The mean age of participants was 43.8 years; 82.9% were female, 51.2% had episodic migraine, and 48.8% had chronic migraine. Prior to trial participation, patients identified pain, nausea, and profound tiredness-often expressed as a "lack of energy" or feeling "exhausted" or "drained"-as the most bothersome symptoms. Patients also emphasized difficulties concentrating, interference with school, work, and household responsibilities, and emotional strain as the most bothersome impacts of living with migraine. At the end of the trial, patients reported important improvements in their migraine experience-such as reductions in migraine frequency, severity, and duration-which translated into tangible benefits in daily life. Overall, satisfaction with erenumab was high (mean score 6.8 on a 0-10 scale) and was mainly driven by the reduced frequency and duration of migraine. CONCLUSION: Results from this qualitative study confirm that migraine significantly impacts the quality of life of adults in Japan. This study provides valuable insights into patients' experiences of erenumab, which reduced the frequency, severity, or duration of migraine episodes in most patients, resulting in better functioning and overall quality of life. TRIAL REGISTRATION: Clinicaltrials.gov NCT03812224. Registered January 23, 2019.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemaleMaleAdultMiddle AgedDouble-Blind MethodQualitative ResearchJapanQuality of LifeInterviews as TopicTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizederenumabCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, UK. carla.dias-barbosa@evidera.com.
  • Fujitsu Clinic, Kanagawa, Japan.
  • PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, UK.
  • Konan Medical Center, Hyogo, Japan.
  • Tanaka Neurosurgical Clinic, Kagoshima, Japan.
  • Shinagawa Strings Clinic, Tokyo, Japan.

Förderung

  • Amgen

Zitieren

APA

Dias-Barbosa, C., Igarashi, H., Duenas, A., Hareendran, A., Kitamura, S., Tanaka, S., Sanno, N., Doi, H., Nagamitsu, T., Tatsuoka, Y., Matsumori, Y., Hasebe, M., & Takeshima, T. (2026). Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants. The Patient - Patient-Centered Outcomes Research. https://doi.org/10.1007/s40271-026-00813-6

Vancouver

Dias-Barbosa C, Igarashi H, Duenas A, Hareendran A, Kitamura S, Tanaka S, et al. Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants. The Patient - Patient-Centered Outcomes Research. 2026. doi:10.1007/s40271-026-00813-6

BibTeX
@article{DiasBarbosa2026,
  author = {Dias-Barbosa, Carla and Igarashi, Hisaka and Duenas, Ashley and Hareendran, Asha and Kitamura, Shigekazu and Tanaka, Shigeya and Sanno, Naoko and Doi, Hikaru and Nagamitsu, Tsutomu and Tatsuoka, Yoshihisa and Matsumori, Yasuhiko and Hasebe, Miki and Takeshima, Takao},
  title = {Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants},
  journal = {The Patient - Patient-Centered Outcomes Research},
  year = {2026},
  doi = {10.1007/s40271-026-00813-6}
}
Kostenlos starten →